Iovance Biotherapeutics, Inc.
IOVA
Classifica tra le azioni
#2841
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Prezzo delle azioni
$14.57
Capitalizzazione di mercato
$6.60B
Variazione (1 giorno)
2.53%
Variazione (1 anno)
528.02%
Paese
US
Scambia Iovance Biotherapeutics, Inc. (IOVA)
Categoria
Healthcare
Utile per Iovance Biotherapeutics, Inc. (IOVA)
Utile nel Jun 2026 TTM: $-293.78M
Secondo gli ultimi rapporti finanziari di Iovance Biotherapeutics, Inc., gli utili attuali della società sono $-293.78M. Nel 2023, la società ha registrato un utile di $-447.52M, una diminuzione rispetto a agli utili del 2022, che erano di $-395.89M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Iovance Biotherapeutics, Inc. dal 2008 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $-293.78M | -21.66% |
| 2024 | $-375.01M | -16.20% |
| 2023 | $-447.52M | 13.04% |
| 2022 | $-395.89M | 15.67% |
| 2021 | $-342.25M | 31.85% |
| 2020 | $-259.58M | 31.40% |
| 2019 | $-197.56M | 59.86% |
| 2018 | $-123.58M | 34.23% |
| 2017 | $-92.06M | 74.05% |
| 2016 | $-52.89M | 91.23% |
| 2015 | $-27.66M | 129.83% |
| 2014 | $-12.04M | -52.58% |
| 2013 | $-25.38M | 667.26% |
| 2012 | $-3.31M | -87.13% |
| 2011 | $-25.69M | 1,497.89% |
| 2010 | $-1.61M | 10,095.28% |
| 2009 | $-15.77K | -72.40% |
| 2008 | $-57.14K | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | -1,895.55% |
US
|
|
| $-3.09B | 950.80% |
US
|
|
| $-4.02B | 1,267.09% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -763.99% |
NL
|
